| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.ishitadrugs.com | |
| Market Cap | 20.40 Cr. | |
| Enterprise Value(EV) | 18.25 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 2.16 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 31.57 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 42.15 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 32.23 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 2.12 | Calculated using Price: 68.21 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.30 Cr. | 2,990,300 Shares |
| FaceValue | 10 | |
| About Ishita Drugs & Industries Ltd. | ||
| Ishita drugs & industries limited (IDIL), an Ishita Group company was incorporated in 1992, the company is listed on the local stock exchanges in India and has earned a reputation as a 'high quality manufacturer' in a very short time. | ||
| 1 Day |
|
-1.15% |
| 1 Week |
|
-1.36% |
| 1 Month |
|
-0.91% |
| 3 Month |
|
-23.27% |
| 6 Month |
|
+5.99% |
| 1 Year |
|
+36.25% |
| 2 Year |
|
+25.77% |
| 5 Year |
|
+221.71% |
| 10 Year |
|
+398.14% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 4.12 | 2.47 | 3.19 | 4.17 | 5.64 | 8.18 | 11.25 | 9.82 | 6.5 | |
| Return on Capital Employed (%) | 5.98 | 4.02 | 4.79 | 7.26 | 8.17 | 10.79 | 14.39 | 13 | 8.9 | |
| Return on Assets (%) | 3.26 | 1.81 | 2.37 | 3.46 | 4.54 | 6.12 | 8.82 | 7.85 | 5.1 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 5 | 6 | 6 | 6 | 6 | 7 | 8 | 9 | 9 | 10 | |
| Non Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Curr. Liab. | 1 | 3 | 1 | 1 | 2 | 3 | 1 | 3 | 2 | 3 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 7 | 8 | 7 | 7 | 8 | 10 | 9 | 11 | 11 | 13 | |
| Non Curr. Assets | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | |
| Curr. Assets | 6 | 7 | 6 | 6 | 7 | 8 | 8 | 10 | 10 | 12 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 7 | 8 | 7 | 7 | 8 | 10 | 9 | 11 | 11 | 13 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 7 | 7 | 6 | 7 | 9 | 15 | 14 | 14 | 12 | 13 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 7 | 7 | 6 | 7 | 9 | 15 | 14 | 14 | 12 | 14 | |
| Total Expenditure | -7 | -6 | -6 | -6 | -9 | -14 | -13 | -13 | -11 | -12 | |
| PBIDT | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Taxation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Items | |||||||||||
| PAT | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | |
| Adjusted EPS | 1 | 0 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 2 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 1 | 0 | 0 | 1 | 1 | 1 | 1 | -1 | 3 | -3 | |
| Cash Fr. Inv. | 0 | 0 | 0 | -1 | -1 | -1 | -1 | 2 | -1 | 1 | |
| Cash Fr. Finan. | 0 | 0 | 1 | -1 | 0 | 0 | 0 | 0 | 1 | ||
| Net Change | 0 | 0 | 1 | -1 | 0 | 0 | 0 | 2 | 2 | -1 | |
| Cash & Cash Eqvt | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 3 | 5 | 3 |
|
Fri, 03 May 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation about issuance of duplicate share certificate |
|||||||||||||||||||||
|
Thu, 25 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Srushti Pandya Designation: Company Secretary EmailId: ishitadrugs@gmail.com Name of the Chief Financial Officer: Sumit Agrawal Designation: Chief Financial Officer EmailId: ishitadrugs@gmail.com Date: 25/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Mon, 22 Apr 2024
Compliance Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Year Ended 31St March 2024 We are enclosing the certificate received from Ms. Meenu Maheshwari Practicing Company Secretary pursuant to the Regulation 40(9) and 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the year ended 31st March 2024. |
| Fri, 03 May 2024 |
High Delivery Percentage
|
High Decrease in 3 Months
|
High Increase in 1 Year
|
High Increase in 5 Years
|
CCI Trending Down
|
